Drug Combo Proves Powerful Against Lung Cancer Sayville NY

A two-drug combination treatment in Sayville proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Sudha V Mukhi
(631) 422-4545
435 Montauk Hwy
West Islip, NY
Philip Schulman
(646) 227-3813
650 Commack Rd
Commack, NY
ANDRZEJ KUDELKA, MD
(631) 444-2540
University Hospital, L5
Stony Brook, NY
JOHN FIORE, MD
(646) 227-3813
650 Commack Road
Commack, NY
Robert Ingalls Parker, MD
631-444-7720
HSC Toll Rm 029,
Stony Brook, NY
Diane M Clausen
(631) 751-8305
2500 Nesconset Hwy
Stony Brook, NY
Shahid Nawaz
(631) 751-3000
235 N Belle Mead Rd
E Setauket, NY
HEROLD DUROSEAU
(631) 321-2100
655 Deer Park Avenue
Babylon, NY
RANA ZOEB, MD
(631) 447-5445
74 Southaven Avenue
Medford, NY
Li Ge, MD
Huntington Station, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Genetic Clues for Skin Cancer Therapies Sayville NY
Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.
- Hormone Therapy for Lung Cancer Sayville NY
- Delayed Prostate Cancer Therapy Sayville NY
- Risks for Childhood Cancer Survivors Sayville NY
- Exercise for Breast Cancer Survival Sayville NY
- Fungal Infection Treatments Sayville NY
- Exercise for Prostate Cancer Sayville NY
- Hormone Therapy for Breast Cancer Sayville NY
- Side Effect Of Chemotherapy Drugs Sayville NY